{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:01:31Z","timestamp":1787806891426,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ygyno.2023.12.017","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T17:34:05Z","timestamp":1705944845000},"page":"124-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FR\u03b1-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer"],"prefix":"10.1016","volume":"182","author":[{"given":"Mihaela C.","family":"Cristea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Synold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wilczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Dellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2023.12.017_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2023.12.017_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.ygyno.2023.12.017_bb0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.017_bb0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","article-title":"Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy","volume":"130","author":"Despierre","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.017_bb0025","series-title":"ELAHERE Package Insert","year":"2022"},{"issue":"13","key":"10.1016\/j.ygyno.2023.12.017_bb0030","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of Mirvetuximab Soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.12.017_bb0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.017_bb0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2023.12.017_bb0045","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2015.66.0787","article-title":"Double-blind, placebo-controlled, randomized phase III trial evaluating Pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE)","volume":"34","author":"Kurzeder","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10271","key":"10.1016\/j.ygyno.2023.12.017_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.017_bb0055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2010.11.027","article-title":"A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"121","author":"Tait","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.12.017_bb0060","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00001813-199902000-00003","article-title":"Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer","volume":"10","author":"Possinger","year":"1999","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"10.1016\/j.ygyno.2023.12.017_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1054\/brst.2000.0170","article-title":"Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer","volume":"9","author":"Brodowicz","year":"2000","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.ygyno.2023.12.017_bb0070","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.017_bb0075","doi-asserted-by":"crossref","first-page":"S626","DOI":"10.1016\/j.annonc.2020.08.972","volume":"31","author":"O\u2019Malley","year":"2020","journal-title":"Ann. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2023.12.017_bb0080","first-page":"A33","article-title":"18\/#499\u00a0Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis","volume":"32","author":"Moore","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"17_suppl","key":"10.1016\/j.ygyno.2023.12.017_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507","volume":"41","author":"Moore","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.12.017_bb0090","series-title":"Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha\u2013Targeting Antibody\u2013Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study","first-page":"1112","volume":"35(10)","author":"Moore","year":"2017"},{"key":"10.1016\/j.ygyno.2023.12.017_bb0095","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.ygyno.2023.12.017_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2023.12.017_bb0105","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/JCO.2023.41.16_suppl.5508","volume":"41","author":"Oaknin","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823016232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823016232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T14:56:22Z","timestamp":1719327382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823016232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":21,"alternative-id":["S0090825823016232"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FR\u03b1-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}